Examining the use of bempedoic acid in preventing cardiovascular events in patients who are statin- intolerant

Mean participant age was 68 years, 59% were female, and 66% had diabetes. Participants were randomized to oral bempedoic acid, 180 mg daily or matching placebo.

Main Outcome Measures The primary efficacy measure was the time from randomization to the first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.

From a mean baseline of 142.5 mg/dL, compared with placebo, bempedoic acid reduced low-density lipoprotein cholesterol levels by 21.3%) and high-sensitivity C-reactive protein levels by 21.5%).. Follow-up for a median of 39.9 months was associated with a significant risk reduction for the primary end point and key secondary end points.

Reference: Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. Published online June 24, 2023. doi:10.1001/jama.2023.9696